Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Innovative treatment strategies for multiple myeloma

Ruben Niesvizky • 25 Oct 2021
LLM 2021
Multiple Myeloma Iberdomide Melflufen Selinexor

Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, comments on new developments in treatments for multiple myeloma. Novel immunomodulating agents such as iberdomide and other cereblon E3 ligase modulators (CELMoDs) have shown promising results and could be given in combination with other immunological therapies. In addition, new drugs, including selinexor and melflufen are now available in the relapsed/refractory setting and could potentially be used in earlier lines of treatment. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Ruben Niesvizky

2:51
Key myeloma discussion topics at LLM 2021
Ruben Niesvizky • 25 Oct 2021
1:25
Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting
Ruben Niesvizky • 25 Oct 2021
1:22
Using molecular techniques to define risk in patients with myeloma
Ruben Niesvizky • 25 Oct 2021

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals